Orexin

Cerevance Announces Publication of CVN766 in Bioorganic & Medicinal Chemistry Letters

Retrieved on: 
Thursday, February 15, 2024
Therapy, Central nervous system, Schizophrenia, Sleep, DSM-IV codes, Food, Orexin, Behavior, CNS, Locus coeruleus, Motivation, Publication, Somnolence, ACS Medicinal Chemistry Letters, Pharmaceutical industry

BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters.

Key Points: 
  • BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced a publication describing the discovery and initial development of CVN766 in the peer-reviewed journal, Bioorganic & Medicinal Chemistry Letters.
  • In the publication titled, “Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist,” the authors describe the development of CVN766 to be over 1,000-fold more selective for the orexin 1 receptor (Ox1R) than the orexin 2 receptor (Ox2R).
  • Dysfunction of this target, Ox1R, is implicated in psychiatric disorders, such as schizophrenia, addictions (including food), and anxieties.
  • “CVN766 has demonstrated high brain permeability, prolonged receptor occupancy, and a pharmacokinetic and safety profile suitable for clinical evaluation across various psychiatric indications,” said Mark Carlton, Ph.D., chief scientific officer for Cerevance.

Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia

Retrieved on: 
Monday, January 9, 2023
Dizziness, Headache, CNS, Pharmacokinetics, Safety, Fatigue, PK, Lightheadedness, SAD, AUC, Cmax, Neurological disorder, Orexin, Central nervous system, Patient, Somnolence, MAD, AES, Schizophrenia, UU, Pharmaceutical industry, Cerev Del

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced positive results from its Phase 1 study of CVN766 in healthy subjects. The trial was a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and pharmacokinetics (PK) of escalating single and multiple doses of CVN766 in 64 healthy subjects. This data, along with earlier preclinical studies, supports developing CVN766 as a potential treatment for negative and cognitive symptoms of schizophrenia.

Key Points: 
  • This data, along with earlier preclinical studies, supports developing CVN766 as a potential treatment for negative and cognitive symptoms of schizophrenia.
  • CVN766 was well tolerated with an excellent safety profile across all dose groups: Data across all dose cohorts showed that CVN766 was well tolerated with a favorable safety profile.
  • There were no serious adverse or dose-limiting adverse events (AEs), treatment-related discontinuations, or meaningful changes in clinical laboratory parameters or physical exams.
  • “We are encouraged with the safety and pharmacokinetics profiles observed in the Phase 1 trial for CVN766,” said Craig Thompson, chief executive officer of Cerevance.

Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist

Retrieved on: 
Wednesday, May 4, 2022
Sleep, Neuroscience, Jazz Pharmaceuticals, Narcolepsy, Psychiatry, Twitter, Health, EDS, Pharmacokinetics, Sleep paralysis, NASDAQ, Idiopathic hypersomnia, Excessive daytime sleepiness, Safety, Drug discovery, Patient, Commission, Risk, Orexin, Annual report, DNS, U.S. Securities and Exchange Commission, Sleep disorder, Neurology, Wakefulness, Cataplexy, Research, Head, Neuropeptide, Pharmaceutical industry, TSE, Jazz

DUBLIN and OSAKA, Japan, May 4, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) today announced that the companies have entered into an exclusive licensing agreement under which Jazz has acquired development and commercialization rights in the United States, Europe and other territories for Sumitomo Pharma's investigational DSP-0187, a potent, highly selective oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders. Jazz has designated this molecule JZP441.

Key Points: 
  • Sumitomo Pharma initiated a Phase 1 trial in Japan of DSP-0187 in November 2021 to evaluate safety, tolerability and pharmacokinetics in healthy volunteers.
  • "Orexin agonism is an exciting area of sleep disorder research and an approach that may be complementary to oxybate therapy.
  • "DSP-0187 is a potent, highly selective oral orexin-2 receptor agonist, which is a novel small molecule compound originally created by Sumitomo Pharma by utilizing our advanced expertise in drug discovery for central nervous system disorders.
  • DSP-0187 is a potent, highly selective orexin-2 receptor agonist designed to activate orexin signaling.

Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766

Retrieved on: 
Tuesday, January 25, 2022
Reward, Schizophrenia, Neurological disorder, Pharmacokinetics, Orexin, Collection, Brain, Cerev Del, Therapy, Plasma, Technology, Anxiety, Neuroscience, Panic, Disease, Peripheral nervous system, Sleep, Patient, Biomarker, Lists of diseases, Panic disorder, Fear, GLOBE, CNS, Safety, Pharmaceutical industry, Medical imaging

BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the dosing of the first human subjects in a Phase 1 clinical trial of its compound, CVN766.

Key Points: 
  • BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the dosing of the first human subjects in a Phase 1 clinical trial of its compound, CVN766.
  • CVN766 was found to be effective in various animal models of psychiatric diseases, including reversing nicotine-induced stress in rodents and acute stress behaviors in non-human primate models of panic.
  • The Phase 1, randomized, double-blind, placebo-controlled trial will assess the safety, tolerability and pharmacokinetics of escalating single and multiple doses of CVN766 in healthy subjects.
  • Cerevance is continuing to actively enroll patients in the Phase 1 study.

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)

Retrieved on: 
Wednesday, July 28, 2021
Research, Medical Supplies, FDA, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Branches of biology, Sleep disorders, Molecular neuroscience, Neuropeptides, Neuroscience, Amphetamine, Narcolepsy, G protein-coupled receptors, Orexin, Cataplexy, Hypocretin (orexin) receptor 2, Danavorexton

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.
  • Individuals with narcolepsy type 1 suffer from excessive daytime sleepiness, which might mean routinely falling asleep at work or in school.
  • This designation marks a key milestone in Takedas accelerated development efforts to bring this important potential therapy to patients with NT1.
  • A Study of TAK-994 in Participants With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 [NT1] or Narcolepsy Type 2 [NT2]).

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

Retrieved on: 
Thursday, July 1, 2021
Branches of biology, Biology, G protein-coupled receptors, Orexin antagonist, Eisai, Orexin receptor, Insomnia, Orexin, Hong Kong Airlines, Sleep

TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Key Points: 
  • TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • Eisai received approval for DAYVIGO in Hong Kong on February 28, 2021, and this launch is the first for DAYVIGO in Asia outside of Japan.
  • (10)
    The anti-insomnia drug market in Hong Kong as of 2020 valued at approximately 8.4 million USD, comprising nearly 9% of the insomnia drug market in Asia (Hong Kong, India, Indonesia, Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand).
  • Sleep.

NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation for Treating Narcolepsy

Retrieved on: 
Tuesday, May 18, 2021
Psychoactive drugs, Branches of biology, Molecular neuroscience, Neuroscience, Stimulants, Sleep disorders, Neuropeptides, Chloroarenes, Orexin, Mazindol, Reuptake inhibitor, Narcolepsy

Narcolepsy is caused by a deficiency in orexin, a neuropeptide that regulates the sleep-wake cycle.

Key Points: 
  • Narcolepsy is caused by a deficiency in orexin, a neuropeptide that regulates the sleep-wake cycle.
  • NLS believes that the new data also support prior in-vitro data from studies conducted by the Company demonstrating the partial binding affinity of mazindol to OX2R, which NLS believes is a key pathway that mediates mazindol\'s stimulant-like effects.
  • We believe that Quiliencewill provide a differentiated solution in this treatment category given mazindol\'s dual mechanism of action, namely orexin pathway activation and pan-monoaminergic reuptake inhibition in the brain.
  • NLS completed a Phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD.

Chronic Insomnia Market Expected to Thrive at a CAGR of 7.29% for the Study Period 2018-2030 in the 7MM, Estimates DelveInsight

Retrieved on: 
Thursday, April 22, 2021
Branches of biology, Sleep disorders, Neuroscience, Biology, Insomnia, Psychiatric diagnosis, Mental states, Orexin, Chronic condition, Sleep

b"LAS VEGAS, April 22, 2021 /PRNewswire/ -- The Chronic Insomnia Market report offers a comprehensive analysis of the disease overview, its causes, signs/ symptoms, and diagnosis modalities.

Key Points: 
  • b"LAS VEGAS, April 22, 2021 /PRNewswire/ -- The Chronic Insomnia Market report offers a comprehensive analysis of the disease overview, its causes, signs/ symptoms, and diagnosis modalities.
  • As per DelveInsight's Chronic Insomnia epidemiological analysis, Chronic Insomnia is slightly more prevalent among females than males.\nThe Chronic Insomnia market report offers historical and forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:\nThe primary goal of the Chronic Insomnia market is to improve sleeping habits and alleviate symptoms such as distress and dysfunction.
  • Orexin receptor antagonists, including Dayvigo and Belsomra, recently gained popularity in the Chronic Insomnia market therapy.\nReach out to us @ Chronic Insomnia Market Landscape, Growth, Drivers and Barriers\nHowever, several limitations exist in the present Chronic Insomnia market.
  • An increased understanding and screening of insomnia disorder by health care professionals could result in broader public knowledge of insomnia disorder and sleep health.\n"

Chronic Insomnia Market Expected to Thrive at a CAGR of 7.29% for the Study Period 2018-2030 in the 7MM, Estimates DelveInsight

Retrieved on: 
Thursday, April 22, 2021
Branches of biology, Sleep disorders, Neuroscience, Biology, Insomnia, Psychiatric diagnosis, Mental states, Orexin, Chronic condition, Sleep

b"LAS VEGAS, April 22, 2021 /PRNewswire/ -- The Chronic Insomnia Market report offers a comprehensive analysis of the disease overview, its causes, signs/ symptoms, and diagnosis modalities.

Key Points: 
  • b"LAS VEGAS, April 22, 2021 /PRNewswire/ -- The Chronic Insomnia Market report offers a comprehensive analysis of the disease overview, its causes, signs/ symptoms, and diagnosis modalities.
  • As per DelveInsight's Chronic Insomnia epidemiological analysis, Chronic Insomnia is slightly more prevalent among females than males.\nThe Chronic Insomnia market report offers historical and forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:\nThe primary goal of the Chronic Insomnia market is to improve sleeping habits and alleviate symptoms such as distress and dysfunction.
  • Orexin receptor antagonists, including Dayvigo and Belsomra, recently gained popularity in the Chronic Insomnia market therapy.\nReach out to us @ Chronic Insomnia Market Landscape, Growth, Drivers and Barriers\nHowever, several limitations exist in the present Chronic Insomnia market.
  • An increased understanding and screening of insomnia disorder by health care professionals could result in broader public knowledge of insomnia disorder and sleep health.\n"

Seltorexant: An Innovative Selective Orexin 2 Receptor Antagonist Under Development for the Treatment of Major Depressive Disorder - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 12, 2021
Pharmaceutical, Health, Mental health, Antidepressants, Psychoactive drugs, Drugs, Branches of biology, Seltorexant, Orexin, Major depressive disorder, Depressive, TS-121, BTRX-335140

Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of Major Depressive Disorder.

Key Points: 
  • Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of Major Depressive Disorder.
  • "Seltorexant- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Major Depressive Disorder in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Which are the late-stage emerging therapies under development for the treatment of Major Depressive Disorder?